ArticleCurrent clinical microbiology reports2019
Article in Current clinical microbiology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 22 citations in OpenAlex.
- Harnessing live vectors for cancer vaccines: Advancing therapeutic immunotherapy.Human vaccines & immunotherapeutics · 2025Review
- Engineered Endosymbionts that Modulate Primary Macrophage Function and Attenuate Tumor Growth by Shifting the Tumor Microenvironment.ACS applied bio materials · 2025Article
- Long-Lasting, Fine-Tuned Anti-Tumor Activity of RecombinantPathogens (Basel, Switzerland) · 2024Article
- Cytosolic bacterial pathogens activate TLR pathways in tumors that synergistically enhance STING agonist cancer therapies.bioRxiv : the preprint server for biology · 2024Article
- Type I Interferon Signaling on Antigen-Presenting Cells Blunts Cell-Mediated Immunity toward Listeria monocytogenes.Infection and immunity · 2023Article
- Bacterial Therapy of Cancer: A Way to the Dustbin of History or to the Medicine of the Future?International journal of molecular sciences · 2023Review
- Human Listeriosis.Clinical microbiology reviews · 2023Review
- Microbiota and cancer: current understanding and mechanistic implications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Listeria-based immunotherapy directed against CD105 exerts anti-angiogenic and anti-tumor efficacy in renal cell carcinoma.Frontiers in immunology · 2022Article
- Microbiome engineering: engineered live biotherapeutic products for treating human disease.Frontiers in bioengineering and biotechnology · 2022Review
- Non-human Primate Models to Investigate Mechanisms of Infection-Associated Fetal and Pediatric Injury, Teratogenesis and Stillbirth.Frontiers in genetics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purpose of the reviewImmunotherapy has emerged as a promising cancer treatment, however success in only select clinical indications underscores the need for novel approaches. Recently RECENT
findingsRecent studies indicate that in addition to inducing antigen specific T-cell responses, SUMMARY: The interplay between innate and adaptive immune responses to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.